Fumihiko Hinoshita
Research Subjects
Research Interests
Fumihiko Hinoshita has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ayumi Yoshifuji
Department of Infectious Diseases, Keio University School of Medicine
1 shared publication - Emi Oyama
Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan
1 shared publication - Hidetomo Nakamoto
Department of Nephrology, Saitama Medical School, Saitama
1 shared publication - Hirofumi Kon
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
1 shared publication - Junko Tanaka
Department of Epidemiology, Infectious Disease Control, and Prevention Hiroshima University Institute of Biomedical and Health Sciences Hiroshima Japan
1 shared publication - Kan Kikuchi
Division of Nephrology, Shimoochiai Clinic, Tokyo 161-0033, Japan
1 shared publication
Latest Publications
- Open Access
- 7 September 2022
- Published by MDPI AG in Preprints.org
T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis
Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control.
- 7 September 2022
- Published by MDPI AG in Preprints.org
Open AccessT-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis
Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control.